Explore

Genetic Variants Linked to Varied Responses to Obesity Drugs Identified by 23andMe

Genetic Variants Linked to Varied Responses to Obesity Drugs Identified by 23andMe

A study published in Nature by 23andMe has identified genetic variants that explain the varied responses to obesity drugs like semaglutide and tirzepatide. The research involved nearly 28,000 participants who used 23andMe's DNA-testing service and reported their experiences with weight-loss drugs. The study found that specific genetic variants are associated with greater weight loss and increased risk of side effects such as nausea. These findings provide insights into why some individuals experience significant weight loss while others do not, highlighting the role of genetics in drug efficacy and side effects.

Shionogi Secures U.S. Government Contract to Combat Drug-Resistant Bacterial Threats

Shionogi Secures U.S. Government Contract to Combat Drug-Resistant Bacterial Threats

Shionogi Inc., a subsidiary of the Japanese pharmaceutical company Shionogi & Co., Ltd., has been awarded a contract by the U.S. government through the Biomedical Advanced Research and Development Authority’s (BARDA) Project BioShield. The contract, initially funded at $119 million with options extending up to $482 million, aims to enhance national preparedness against drug-resistant bacterial threats. The funding will support the establishment of a U.S. manufacturing site for Fetroja, a drug used to treat infections caused by high-priority biothreat pathogens such as Burkholderia pseudomallei and Yersinia pestis. Additionally, the contract will facilitate the procurement and development of Fetroja for pediatric patients with hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia.

NIH Researchers Develop New Opioid with Reduced Addiction Risk

NIH Researchers Develop New Opioid with Reduced Addiction Risk

Researchers at the National Institutes of Health (NIH) have developed a new opioid compound that offers strong pain relief without the typical risks of addiction and respiratory depression. This new compound, derived from a class of synthetic opioids known as nitazenes, was tested in laboratory animals and showed promising results. The study, published in Nature, highlights the compound's ability to provide effective pain relief while minimizing adverse effects commonly associated with opioids. The research team focused on modifying the nitazenes to retain their pain-relieving properties while reducing their potency to improve safety. The compound, referred to as DFNZ, demonstrated a safer pharmacological profile, avoiding respiratory depression and showing minimal withdrawal symptoms in preclinical tests.

SoundCell's Graphene Drums Revolutionize Bacterial Identification in Hospitals

SoundCell's Graphene Drums Revolutionize Bacterial Identification in Hospitals

SoundCell, a spinoff company from TU Delft in the Netherlands, has developed a groundbreaking technology using nanoscale graphene drums to identify bacteria by sound. This innovative approach allows researchers to diagnose bacterial infections by listening to the acoustic patterns generated by bacteria's movements. The technology, which can quickly screen for antibiotic resistance, has been refined to identify different bacteria species based on their unique sounds. SoundCell's device, now deployed in two hospitals in the Netherlands, aims to provide rapid and accurate bacterial identification, potentially reducing the time required for antibiotic resistance testing from days to just an hour.

Graphene Nanodrums Enable Bacterial Identification by Sound

Graphene Nanodrums Enable Bacterial Identification by Sound

Researchers at TU Delft and SoundCell have developed a novel method to identify bacteria using sound, employing nanoscale graphene drums. These 'nanodrums' convert the movements of bacteria into acoustic patterns, allowing for the identification of bacterial species and their antibiotic resistance. The technology has shown that different bacteria produce distinct sounds, which can be used to diagnose infections and determine antibiotic efficacy. This method offers a rapid alternative to traditional bacterial identification techniques, potentially transforming diagnostic practices in healthcare settings.

NanoViricides Files for Rare Pediatric Disease Drug Designation for Measles Treatment NV-387

NanoViricides Files for Rare Pediatric Disease Drug Designation for Measles Treatment NV-387

NanoViricides Files for Rare Pediatric Disease Drug Designation for Measles Treatment NV-387

NeuroTherapia Completes Phase 2a Trial for Alzheimer's Treatment NTRX-07

NeuroTherapia Completes Phase 2a Trial for Alzheimer's Treatment NTRX-07

NeuroTherapia Completes Phase 2a Trial for Alzheimer's Treatment NTRX-07

23andMe Study Identifies Genetic Variants Affecting Obesity Drug Efficacy and Side Effects

23andMe Study Identifies Genetic Variants Affecting Obesity Drug Efficacy and Side Effects

A study conducted by the research arm of genetic testing company 23andMe has identified genetic variations that influence the effectiveness and side effects of GLP-1 agonist-based weight-loss drugs. The study analyzed the genomes of nearly 28,000 users of these drugs, including Novo Nordisk's Wegovy and Eli Lilly's Zepbound. Researchers found a missense variant in the GLP1R gene associated with greater weight loss and multiple variants in the GIPR gene linked to increased susceptibility to side effects like nausea and vomiting. These findings, published in the journal Nature, suggest that genetic testing could help tailor weight-loss treatments to individual patients, enhancing efficacy and safety.

Amgen's New Tepezza Formulation Shows Promise in Phase 3 Trials

Amgen's New Tepezza Formulation Shows Promise in Phase 3 Trials

Amgen's New Tepezza Formulation Shows Promise in Phase 3 Trials

AI-Driven Discovery of Antimicrobial Peptides from Extreme Environments Promises New Antibiotics

AI-Driven Discovery of Antimicrobial Peptides from Extreme Environments Promises New Antibiotics

Researchers have utilized artificial intelligence to identify antimicrobial peptides from microorganisms inhabiting Earth's extreme environments, as detailed in a recent study published in Nature Communications. The study introduced the Extreme Environment Microbiome Catalog (EEMC), a comprehensive resource that reconstructs over 78,000 genomes from diverse extreme habitats, such as deep-sea vents and cryospheric systems. This catalog has enabled the identification of thousands of candidate antimicrobial peptides (cAMPs), many of which show activity against difficult-to-treat Gram-negative pathogens. The research highlights the potential of these peptides as next-generation antimicrobials, addressing the critical issue of antimicrobial resistance and the slowdown in antibiotic discovery.

US Government Launches $144M Initiative to Combat Microplastics in Human Body

US Government Launches $144M Initiative to Combat Microplastics in Human Body

The United States Department of Health and Human Services (HHS) has announced a $144 million initiative to address the issue of microplastics in the human body. The program, named Systematic Targeting Of MicroPlastics (STOMP), aims to measure microplastics and nanoplastics in human bodies and research their effects. HHS Secretary Robert F. Kennedy, Jr. emphasized the need for clear answers regarding the health impacts of microplastics. The initiative will focus on developing tools to measure microplastic exposure, identify sources of risk, and create solutions to reduce their presence in the body. The program will be led by ARPA-H and aims to establish standardized measurement methods and interventions to address microplastic-related health concerns.

Evommune to Explore MRGPRX2 Inhibition for Migraine Treatment

Evommune to Explore MRGPRX2 Inhibition for Migraine Treatment

Evommune to Explore MRGPRX2 Inhibition for Migraine Treatment